RA Efficacy

An in-depth look at the data in RA

KINERET was studied in 899 patients with active RA1

This randomized, double-blind, placebo-controlled trial was conducted on 899 patients with active RA who had been on a stable dose of methotrexate (10-25 mg/week) for at least 8 weeks. Patients were randomized to KINERET (n=250) or placebo (n=251) in addition to their stable doses of methotrexate. The first 501 patients were evaluated for signs and symptoms of active RA.

ACR statistics infographic

*17% + 6% = 23%.

Two horizontal bar charts showing ACR response at 6 months. The top bar, KINERET + methotrexate, shows a 6% ACR response and the lower bar, placebo + methotrexate, shows a 2% ACR response
ACR statistics infographic

Patients using KINERET saw improvements in ACR component scores1

In addition to swollen, tender, or painful joints, elevated ESR and CRP levels can indicate systemic autoinflammation, which KINERET has been shown to control in refractory RA patients.

A 24-week study was conducted in 242 patients with active RA on background methotrexate who were randomized to receive either etanercept alone or the combination of KINERET and etanercept. The ACR50 response rate was 31% for patients treated with the combination of KINERET and etanercept and 41% for patients treated with etanercept alone, indicating no added clinical benefit of the combination over etanercept alone. Serious infections were increased with the combination compared to etanercept alone.

Two overlapping squares that are transparent

At 6 months, KINERET DEMONSTRATED REDUCTION IN OBJECTIVE MEASURES like acute-phase reactant levels1:

  • ESR decreased by nearly half (47.2%) from baseline
  • CRP levels decreased by 77% from baseline
ACR score chart

aHealth Assessment Questionnaire (HAQ); 0 = best, 3 = worst; includes 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. bVisual analog scale; 0 = best, 100 = worst. cScale 0 to 68. dScale 0 to 66.

Two overlapping squares that are transparent

At 6 months, KINERET DEMONSTRATED REDUCTION IN OBJECTIVE MEASURES like acute-phase reactant levels1:

  • ESR decreased by nearly half (47.2%) from baseline
  • CRP levels decreased by 77% from baseline

Radiographic changes improved over the course of 1 year with KINERET1

The effect of KINERET on the progression of structural damage was assessed by measuring the change from baseline at month 12 in the TMSS and its subcomponents, erosion score, and JSN score. Radiographs of hands/wrists and forefeet were obtained at baseline, 6 months, and 12 months and scored by readers who were unaware of treatment group. Differences between placebo and KINERET for change in TMSS, ES, and JSN score were observed at 12 months.

The disability index of the HAQ was administered monthly for the first 6 months and quarterly thereafter during the study.

Health outcomes were assessed by the Short Form-36 (SF-36) questionnaire. The 1-year data on HAQ in Study 1 showed more improvement with KINERET than placebo. The physical component summary score of the SF-36 also showed more improvement with KINERET than placebo but not the mental component summary.

Prescribe KINERET
A chart labeled mean radiographic changes over 12 months. The first group of bars measures total sharp score with placebo + MTX vs KINERET 100 mg + MTX with the KINERET arm lower by 0.9. The second group of bars measures erosion with placebo vs KINERET with the KINERET arm lower by  0.5. The final group of bars shows joint space narrowing with placebo vs KINERET and the KINERET arm is lower by 0.4

eDifferences and 95% confidence intervals for the differences in change scores between placebo/MTX and KINERET/MTX. fBased on Wilcoxon rank sum test. MTX, methotrexate.

Two overlapping squares that are transparent

Following 1 year of treatment, TMSS CHANGES WERE 42% LESS IN KINERET PATIENTS compared with placebo.1

Prescribe KINERET